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Abstract: This study aimed to formulate floating gastroretentive tablets containing metformin 
hydrochloric acid (HCl), using various grades of hydrogel such as tamarind powders and xanthan 
to overcome short gastric residence time of the conventional dosage forms. Different concentra-
tions of the hydrogels were tested to determine the formulation that could provide a sustained 
release of 12 h. Eleven formulations with different ratios of tamarind seed powder/tamarind 
kernel powder (TKP):xanthan were prepared. The physical parameters were observed, and in 
vitro drug-release studies of the prepared formulations were carried out. Optimal formulation 
was assessed for physicochemical properties, thermal stability, and chemical interaction fol-
lowed by in vivo gamma scintigraphy study. MKP3 formulation with a TKP:xanthan ratio of 
3:2 was found to have 99.87% release over 12 h. Furthermore, in vivo gamma scintigraphy 
study was carried out for the optimized formulation in healthy New Zealand White rabbits, and 
the pharmacokinetic parameters of developed formulations were obtained. 153Sm
2
O
3
 was used 
to trace the profile of release in the gastrointestinal tract of the rabbits, and the drug release 
was analyzed. The time (T
max
) at which the maximum concentration of metformin HCl in the 
blood (C
max
) was observed, and it was extended four times for the gastroretentive formulation 
in comparison with the formulation without polymers. C
max
 and the half-life were found to be 
within an acceptable range. It is therefore concluded that MKP3 is the optimal formulation for 
sustained release of metformin HCl over a period of 12 h as a result of its floating properties 
in the gastric region.
Keywords: drug delivery systems, floating system, gastric retention, sustained release natural 
polymers, evaluation in vitro and in vivo
Introduction
Polymers have various applications in pharmaceutical sciences, often being used as 
gel-forming agents, binders, diluents, thickeners, and protective colloids in liquids, 
suppositories, suspensions, and cosmetic products.1,2 Polymers are either hydrophilic 
or hydrophobic in nature.3 Depending on their derivation, they can be categorized as 
either synthetic or natural. Natural polymers, such as gums and mucilage, are more 
appealing than synthetic polymers for pharmaceutical applications because they are 
cheaper, easily available, nontoxic, and biodegradable.4 They are also more accept-
able to patients because they have fewer side effects compared to synthetic polymers.5 
Gums and mucilage are plant hydrocolloids and polymers of monosaccharides or 
polysaccharides. Gums are pathological plant products that are formed by dissolving 
the cell walls caused by injury to the plant or by unfavorable growth conditions,6 while 
mucilage is a normal physiological product of metabolism.7 
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Tamarind (Tamarindus indica Linn), from Leguminosae 
family, is an evergreen tree which grows in South Asia. 
A tamarind fruit includes up to six seeds. The seed consists 
of 35%–40% husk and 60%–65% kernel.8 Tamarind seed 
polysaccharide is a mucilaginous polysaccharide that is 
obtained from tamarind seed kernels.9,10 
Tamarind powder has gelling, creaming, and film forming 
properties. It is a good source of polysaccharides and forms 
mucilaginous dispersions with cold water; in addition, the 
viscosity can be increased when it is heated for 20–30 min 
at 100°C. Another advantage is that boiling does not affect 
the properties of polysaccharides.11 Kernel powder contains 
46%–48% of gel-forming polysaccharides.12 
Oral administration is the most convenient route and car-
ries the lowest cost, which leads to high patient compliance.13,14 
Drugs with a short half-life are eliminated from the systemic 
circulation before complete absorption, requiring frequent 
dosing to achieve optimal therapeutic effects. However, 
frequent dosing often leads to increased side effects.15 To 
overcome this limitation, oral controlled-release formulations 
are designed to sustain an effective concentration of the drug 
in the body for an extended period of time by moderating 
the absorption rate.16 
The gastroretentive drug delivery system (GRDDS) is 
a unique approach in oral drug delivery; its purpose is to 
improve drug bioavailabity.16,17 Floating drug delivery sys-
tems offer a number of applications for local acting drugs 
or those which absorb from the upper region of the gastro-
intestinal tract.18,19
Metformin hydrochloric acid (HCl) is an antihyperglycemic 
agent used to decrease glucose levels to manage type II 
diabetes. It has very high water solubility (.300 mg/mL 
at 25°C), poor permeability in the lower area of the gas-
trointestinal (GI) tract, and is mainly absorbed in the upper 
GI; therefore, a floating gastroretentive matrix tablet can be 
helpful in achieving maximum absorption and bioavailability 
of the drug.20
The current study was aimed to design and improve 
floating gastroretentive properties of formulations using 
tamarind powders by a wet granulation process. The pri-
mary goal was to prepare matrix tablets with short floating 
lag time (FLT), required floating and swelling properties, 
and .90% drug release in the predicted period of time. The 
effects of combining tamarind seed powder (TSP)/tamarind 
kernel powder (TKP) and xanthan on gel-forming properties, 
floating behavior, and the release pattern of metformin HCl 
were estimated. 
Materials and methods
White crystalline powder of metformin HCl BP 98 (batch 
no 2011MP0244, 99.61% purity) was obtained from Euro 
Chemo-Pharma Sdn. Bhd (Selangor, Darul Ehsan, Malaysia). 
Tamarind seeds were supplied by Research Laboratory of 
Amritum Bio-Botanica Herbs Pvt Ltd (Indore, India). Lactose 
(C
12
H
22
O
11
⋅H
2
O, M =360.31 g/mol), sodium bicarbonate 
(NaHCO
3
, M =84.01 g/mol), cellulose microcrystalline 
(C
6
H
10
O
5
)
n
, pure xanthan, talc, magnesium stearate, HCl 37% 
(M =36.46 g/mol), and potassium chloride (KCl, M =74.56 g/mol) 
were purchased from R&M Marketing (Saffron Walden, UK). 
Potassium dihydrogen phosphate, perchloric acid 60% solu-
tion, orthophosphoric acid, sodium dodecyl (lauryl) sulfate, and 
acetonitrile were purchased from Thermo Fisher Scientific.
TsP and TKP collection and preparation
TSP and TKP were prepared from tamarind seeds. The 
seeds obtained from India were a mixture of intact seeds and 
broken seeds. Intact seeds were cleaned and handpicked to 
make sure that no traces of pulp existed on the seeds. Both 
de-husking and grinding processes were performed by a 
milling cutter machine (Retsch-Allee, Haan, Germany). 
After running the machine several times, the remaining 
seeds’ husks were removed from the small particles using 
a sharp knife. Then, the complete de-husked seed particles 
were subsequently ground into powder (TKP) using a blender 
machine and sieved into 0.149 mm using a no 100 sieve. 
On the other hand, TSP was produced by grinding the whole 
seed including the husk, and the whole seed was fed into the 
cutting mill machine to be converted to small particle size and 
then powdered using a blender and finally passed through a 
no 100 sieve to standardize the size of particles.21 The TSP 
and TKP were then stored in an airtight polypropylene bottle 
and kept in a desiccator until use.21 
Matrix tablet preparation using 
TsP and TKP
The gastroretentive floating tablets were formulated by the 
wet granulation method using pulverized TSP and TKP, xan-
than, sodium bicarbonate, lactose, microcrystalline cellulose, 
lubricant, and glidant (magnesium stearate and talc). All the 
ingredients were passed through sieve no 100 to get a uniform 
size of 0.149 mm and accurately weighed by employing an 
analytical balance (MS-S/MS-L models; Mettler-Toledo 
AG Laboratory & Weighing Technologies, Greifensee, 
Switzerland). Different formulations were prepared using 
the above ingredients at different concentrations, as shown in 
Table 1. Eight formulations of MSP2/MKP2, MSP3/MKP3, 
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MSP4/MKP4, and MSP5/MKP5 were designed using tama-
rind gum:xanthan in the ratios of 4:1, 3:2, 2:3, and 1:4, respec-
tively. MKP1/MSP1 and MKP6/MSP6 were formulated 
using only TSP/TKP and xanthan, respectively. To prepare 
the tablets, all ingredients except the lubricant and glidant 
were initially mixed using the geometrical dilution method. 
The binder solution (1% w/v xanthan) was used to granulate 
the powder mixture; then the granules were sieved into 2 mm 
using a no 10 sieve and dried out at 50°C in a hot air oven to 
reach a constant moisture level; then sieve no 18 was used 
to sieve the dried granules to obtain a uniform size of 1 mm. 
Premixed talc and magnesium stearate were added to them 
and mixed well to achieve a uniform blend.21 The lubricated 
granules (783 mg) were manually loaded into the die cavity 
and compressed into tablet form via a Manual Type Single 
Punch Tablet Press machine (MTCM-I; GlobePharma, North 
Brunswick, NJ, USA) using a round, concave 12 mm caplet 
punch and compressed at 2200 N.21,22 
evaluation of prepared matrix tablets of 
metformin hcl
The uniformity of content, weight variation, friability, hardness, 
FLT, and total floating time (TFT) of all formulations were 
assessed. The optimal formulation was evaluated by using dif-
ferential scanning calorimetry (DSC), Fourier transform infrared 
spectrometry (FTIR), and X-ray diffraction analysis (XRD).
Weight variation of prepared formulations
Twenty tablets were selected randomly, and the average 
weight was determined by employing an analytical balance 
(MS-S/MS-L models; Mettler-Toledo AG Laboratory & 
Weighing Technologies). Prepared tablets were weighed 
individually to calculate the deviation from individual weight 
of the average weight.23 
Thickness, length, and width of prepared 
formulations
Randomly ten tablets from each formulation were picked, and 
a digital harness tester machine (model 6D; Dr Schleuniger 
Pharmatron, Solothurn, Switzerland) was used to calculate 
the thickness, width, and length of these tablets.24 
hardness of prepared formulations
Ten randomly selected tablets of each formulation were eval-
uated for hardness using a hardness test machine (model 6D; 
Dr Schleuniger Pharmatron).23
Friability of prepared formulations
Ten tablets from each formulation were weighed (W1). 
A friability tester (model Tar10; Erweka, Ensenstam, 
Germany) was run at 25 rpm for 4 min, then the tablets were 
de-dusted and reweighed (W2). The friability was calculated 
using the formula as shown in Equation 1. According to the 
United States Pharmacopeia (USP), a friability of ,1% is 
considered acceptable.25
 Friability = (W1 − W2)/W1 (1)
where W1 is the initial weight of the tablets and W2 is the 
final weight after running the test. 
Prepared tablets drug contents estimation 
Three randomly selected tablets were crushed; 100 mg of the 
crushed powder was added to a volumetric flask and 100 mL 
Table 1 Formulation composition of gastroretentive matrix tablet of metformin hcl
Formulation composition of floating matrix tablets of metformin HCI
Formulation 
code
Ingredients (mg/tablet)
Metformin 
HCl
Polymers* Xanthan MCC Lactose NaHCO3 Magnesium 
stearate
Talc
MsP1 500 100 00 50 50 60 5 5
MsP2 500 80 20 50 50 60 5 5
MsP3 500 60 40 50 50 60 5 5
MsP4 500 40 60 50 50 60 5 5
MsP5 500 20 80 50 50 60 5 5
MKP1 500 100 00 50 50 60 5 5
MKP2 500 80 20 50 50 60 5 5
MKP3 500 60 40 50 50 60 5 5
MKP4 500 40 60 50 50 60 5 5
MKP5 500 20 80 50 50 60 5 5
MKP6/MsP6 500 00 100 50 50 60 5 5
Note: *The polymer is TKP or TsP (depending on the formulation code).
Abbreviations: Mcc, microcrystalline cellulose; TKP, tamarind kernel powder; TsP, tamarind seed powder. 
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of distilled water was added.26 The absorbance of the filtered 
solution was measured using an ultraviolet spectrophotom-
eter (Lambda 35 UV–Vis Spectrometer; PerkinElmer Inc., 
Waltham, MA, USA) at 233 nm.
FLT and TFT of the floating matrix tablets
The time taken by dosage form to rise to the surface and float 
on the media is called FLT, whereas TFT is the maximum 
duration of time that the dosage form stays floating on the 
medium surface.21 TFT and FLT were measured when the 
tablets were inserted into a beaker containing 500 mL of 
simulated gastric fluid (pH 1.2) kept at 37°C. The general 
duration of tablet float was recorded as TFT, and the period 
of time between the insertion of the tablet to the medium and 
its floating to the surface was noted as the FLT.21,27 
in vitro dissolution studies 
An in vitro drug-release test was conducted in a USP dis-
solution apparatus (Copley Scientific Ltd, Nottingham, UK), 
using a paddle speed of 50 rpm in 900 mL of buffer solution 
(pH 1.2), which was maintained at a constant temperature 
of 37°C±0.5°C. Samples of 5 mL were withdrawn from the 
dissolution basket at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 9, 10, 
11, and 12 h and replaced with an equal volume of fresh 
medium.21 The sink condition was followed by replacing the 
amount of sample taken in the dissolution with the dissolu-
tion media.28 All the withdrawn samples were analyzed for 
drug content by measuring the absorbance at 233 nm using 
a UV–visible spectrophotometer. The release profile of each 
formulation was compared to the commercial extended-
release formulation (Glucophage XR, 500 mg; n=3). 
Drug-release kinetics 
The data related to the in vitro dissolution test were assigned 
to mathematical models demonstrating 1) first-order, 2) zero-
order, 3) Hixson–Crowell, and 4) Higuchi’s equations adopted 
from the study performed by Razavi et al.21,22 By using 
pharmacokinetic parameters, the release of metformin HCl 
at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12 h was 
calculated. The percentage of metformin HCl release from the 
effervescent floating tablets was plotted against time.29
characterization of the optimal formulation 
using Dsc
Pure drug, gastroretentive tablets, and polymers (2.5 mg) were 
sealed in aluminum pans for DSC scanning using an auto-
matic thermal analyzer system furnace (model DSC 6,000; 
PerkinElmer). An empty pan sealed in the same way was 
used as a reference. The entire samples were run at a scanning 
rate of 10°C/min from 200°C to 300°C. An experiment was 
performed in a nitrogen atmosphere by purging nitrogen gas 
at 20 mL/min.30 Pyris software (PerkinElmer, Inc., Waltham, 
MA, USA) was used to evaluate the thermograms.31
characterization of the optimal formulation 
using FTir
FTIR spectrum of pure drug, polymers, and best formulation 
was obtained using FTIR (model Nicolet IS10; Thermo 
Scientific, Waltham, MA, USA) in the range of 400–4,000/cm 
using the KBr disc preparation method. The data of IR spec-
tral were analyzed for pure drug, polymers, and the best 
formula using FTIR.32
characterization of the optimal formulation 
using XrD
X-ray diffraction spectra were used to analyze samples using 
an XRD diffractometer (BTX324; Inxitu, Mountain View, 
CA, USA). Pellets were formed by compressing the powder, 
and Cu-Kα radiation (40 kV, 60 mA) used to record the dif-
fractograms. The scanning program was scanned at the rate 
of 2°/min and a speed of 2°/2 cm per 2θ.33
in vivo studies of the optimal formulation 
in rabbits
All the experimental methods were carried out in accordance 
with the approved guidelines protocols from the Institutional 
Animal Care and Use Committee (IACUC) of the Medicine 
faculty, University of Malaya, Kuala Lumpur, Malaysia, and 
the IACUC approved this study (2013-12-03/PHAR/R/MR). 
Male New Zealand White rabbits aged 9–10 weeks weighing 
2.5–3.0 kg were purchased from the IACUC center of the 
University of Malaya. Each rabbit was placed in a clean cage 
and the temperature was controlled to be 22°C–26°C, relative 
humidity of 60%±10%, and alternate 12 h of light and 12 h of 
darkness. They were provided with standard diet ad libitum. 
Before the  experiment, the rabbits were divided into control 
and test groups, with three rabbits in each group.34 
The purpose of the animal work was to evaluate the 
floating behavior of the selected formulation (MKP3) over 
a period of 12 h as well as to compare the drug-release pat-
terns acquired from both in vitro and in vivo tests. The test 
group received the size-reduced formulation of MKP3, and 
the control group received tablets without polymers and 
NaHCO
3
 to investigate the floating ability of these ingredi-
ents to determine the release behavior of the tablet (Table 2). 
The metformin HCl dose was reduced to 250 mg to prevent 
hypoglycemia and to promote easy oral administration of the 
tablets. For pharmacokinetic study, the size-reduced tablets 
were prepared using exactly the same procedures mentioned 
under matrix tablet preparation; the tablets were given to the 
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test and control groups (n=6) and blood samples of 0.5 mL 
were collected from the rabbits’ ear veins at time intervals 
of 0.5, 1, 2, 4, 6, 8, 10, 12, and 14 h; the collected blood was 
immediately transferred to 2 mL sterile containers contain-
ing 10 µL anticoagulant agent (10% w/v sodium citrate). 
The plasma was separated by centrifuging of the samples 
at 3,000 rpm for 20 min. Thus gained plasma samples were 
kept in a refrigerator till further use. 
The preparation of the tablets for in vivo gamma scintigra-
phy study followed exactly the same procedures as mentioned 
in the section of matrix tablet preparation, except that 10 mg 
of samarium-152 (III) oxide (152Sm
2
O
3
) powder was added 
to the ingredients and mixed well. Prior to the in vivo study, 
the release profile and floating properties of the 250 mg 
metformin HCl formulation were tested and compared to 
the previous result, and it showed that the formulations had 
a similar release profile and floating time.
neutron activation of MKP3 tablets for in vivo study
All the test and control tablets used for the in vivo study were 
neutron activated using a nuclear reactor facility situated at 
the Malaysian Nuclear Agency (Bangi, Selangor, Malaysia). 
The facility has a 250 kW open pool-type research reactor 
(Triga Mark II; General Atomics, San Diego, CA, USA), 
which operates a uranium zirconium hydride assembly with 
a low-enriched uranium (20 wt% 235U) fuel source.35 Each 
tablet was heat-sealed in an individual polyethylene vial and 
packed into a polyethylene ampoule (commonly known as the 
“rabbit”). The ampoule was then carried to the reactor core 
by a pneumatic transport system. The tablet was irradiated in 
a neutron flux of 1×1013/cm2/s for 5 min to achieve nominal 
radioactivity of 10 MBq at 48 h after neutron activation.35 
Gamma spectroscopy was carried out 24 h after neutron 
activation using a coaxial, p-type, 40% relative efficiency 
germanium detector (Canberra Inc., Meriden, CT, USA) and 
gamma spectrum analysis software (Genie TM 2000 Ver. 3.2; 
Canberra Inc.) to detect any radioactive impurities.35–37 
in vivo gamma scintigraphy of the rabbits 
The in vivo study was carried out on two separate occasions; 
three rabbits were imaged per day. The rabbits had access to 
only water during the entire day of study.38–40 A pill dispenser 
was used to administer the tablets orally to the rabbits with-
out crushing; this was followed by 30 mL of drinking water 
administered to the rabbit with a sterile syringe. Images 
were taken immediately after drug administration using a 
dual-detector single-photon emission computed tomography-
computed tomography (SPECT-CT) system (BrightView 
XCT; Philips, Eindhoven, the Netherlands) mounted with 
a low energy ultra-high-resolution collimator. The CT 
images were acquired using 120 kVp, 247 mAs, and 1 mm 
slice thickness at 512×512 matrix size, followed by SPECT 
imaging (128×128 matrix size, 64 angulations for 360°, 
15 s per angulation). The total imaging time for a complete 
SPECT-CT acquisition was ~16 min. The acquisition was 
repeated at 1, 2, 4, 6, 8, 10, and 12 h after drug administration. 
Throughout the scanning procedure, the rabbit movements 
were controlled and minimized using a towel. 
The 3D SPECT-CT images were reassembled using 
dedicated software (BrightView XCT workstation; Philips) 
and observed in three different planes, that is, the sagittal, 
coronal, and axial planes (n=3).
HPLC method for the quantification of 
metformin hcl in rabbit plasma
Metformin HCl plasma was extracted with protein precipita-
tion method. An amount of 500 µL of plasma and 50 µL of 
0.05 M HCl were added and vortex-mixed for 30 s; then 2 mL 
of acetonitrile was added. The mixture was centrifuged at 
1,900 × g for 10 min and filtered. The filtrate was evaporated 
to dryness at 40°C and under a nitrogen stream. The extracts 
were reconstituted with 300 µL of mobile phase and 25 µL 
was injected into the HPLC machine at 30°C under isocratic 
conditions with a mobile phase of 34% acetonitrile and 
66% aqueous phase.41 The aqueous phase contained 10 mM 
KH
2
PO
4
 and 10 mM sodium lauryl sulfate. The pH of the 
aqueous phase was adjusted to 5.2 by using dilute orthophos-
phoric acid at a flow rate of 1 mL/min. Eluted metformin HCl 
was detected by ultraviolet rays at 233 nm.42 
Individual plasma concentrations and time curves were 
plotted. Maximum concentration of metformin HCl in blood 
(C
max
), the time at which C
max
 is observed (T
max
), and half-life 
(T
1/2
) were directly calculated from the data and area under 
curve (AUC) was measured using linear trapezoidal rule.
Table 2 composition of test formulation and a control formulation of MKP3 prepared for in vivo study (mg)
MKP3 Metformin 
HCl
TKP Xanthan MCC Lactose NaHCO3 Talc Magnesium 
stearate
Sm2O3
Test 250 30 20 25 25 30 2.5 2.5 10
control 250 – – 25 25 – 2.5 2.5 10
Abbreviations: hcl, hydrochloric acid; Mcc, microcrystalline cellulose; nahcO3, sodium bicarbonate; sm2O3, samarium-152 (iii) oxide; TKP, tamarind kernel powder. 
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Results and discussion
This study was aimed to achieve an extended gastric resi-
dence time and a prolonged presence of the drug in the GI 
tract by taking advantage of the immediate floating and 
swelling properties of the oral dosage form. The develop-
ment of a GRDDS was based on a combination of floatable 
and swellable polymers, such as pulverized tamarind seed, 
xanthan, and NaHCO
3
 as a gas-generating agent. The physi-
cochemical properties of TSP and TKP have been reported in 
a previous study,21 which indicated that both TKP and TSP 
have satisfactory swelling and gelling properties.
evaluation of the matrix tablets
Figure 1 displays the physical appearance of the prepared 
formulations; all the tablets were expected to have the same 
weight and size, but different color due to the difference in the 
type of polymer used (TKP/TSP) and the percentage of poly-
mer used in their composition. The results of characterization 
tests are tabulated in Table 3. All the formulations displayed 
acceptable results and complied with the USP requirements. 
The tablet thickness (n=10) was within the range of 4.6±0.0 
to 4.6±0.9 mm; the average width and length of the prepared 
formulation were 10.1±0.1 to 10.2±0.4 mm and 18.4±0.0 to 
18.4±0.5 mm, respectively. The average weight was between 
764±1 and 765±1 mg (n=20). The drug content for three 
selected tablets from each batch ranged from 97.3%±1% to 
98.9%±0.2%, which was within the standard range.43 The 
hardness of 10 tablets from each batch was assessed, and 
the values of the MSP and MKP formulations were between 
the ranges of 120–280 N and 136–280 N, respectively. All 
formulations had sufficient hardness to withstand abrasion 
and breakage during storage, transportation, and handling 
before use. The formulations with higher concentrations 
of xanthan had greater hardness compared to the others. 
In addition, it was found that the hardness decreased with 
increasing TKP and TSP concentration. The friability test 
for 10 tablets from each formulation was performed; all the 
tablets passed with friability values ,1%, and no obvious 
cracking was observed in any of the tablets.
FlT and TFT
The FLT and TFT behaviors of the tablets are shown in the 
Figure 2. Based on the literature review, it was evident that 
the compression force has a significant effect on the physi-
cal characteristics, floating, and drug-release profile of the 
tablets;44 hence, in the present study, all the formulations 
were compressed with the same force at 2,200 N to mini-
mize the chance of error between the batches. To develop a 
gastroretentive matrix tablet with the shortest FLT, different 
concentrations of NaHCO
3
 were examined. The optimal 
concentration was found to be 60 mg/tablet, which allowed 
a tablet to float within a minute. 
In fact, the FLT of a tablet depends on two factors, 
which are critical to reduce the tablet density to ,1 g/mL: 
1) increases in the bulk volume of the dosage form as a result 
of the hydrocolloids swelling on the tablet surface when it 
comes into contact with gastric juice and 2) the existence of 
voids in the tablet (porosity). The gas-generating agents will 
generate CO
2
 in contact with aqueous media, and the gas will 
be entrapped in the matrix formed by polymers, thus causing 
the tablet to float.18 Channeling agents, such as lactose and 
microcrystalline cellulose, were used in the formulations to 
increase the released drug. These channeling agents fix the 
tablet’s desired dose and easily dissolve in aqueous media to 
form fine channels, thus promoting drug release.
In relation to a previous study,21 the viscosity and swelling 
ability of the polymers were measured. TKP demonstrates 
better swelling index and viscosity in comparison to TSP, 
which can be related to the difference in their structural 
integrity and hydration kinetics.
Immediate floating of the tablets was demonstrated by 
in vitro buoyancy study of the tablet placed in the simulated 
gastric fluid. Floating was influenced by the quantity of 
NaHCO
3
 and the polymer concentration. Tablets exhib-
ited faster FLT when the gas-generating agent was used. 
The buoyancy outcomes obviously proved that increase in 
NaHCO
3
 concentration causes FLT decline, and the FLT 
was shorter in formulations containing TKP and xanthan 
(Figure 2); the TFTs of MKP3, MKP4, MKP5, MKP6, MSP3, 
063 063 063 063 063 063 0.3 0.3 0.3 0.3 0.3 0.3
Figure 1 The physical appearance of different prepared formulations of metformin hcl tablets.
Abbreviation: hcl, hydrochloric acid.
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gastroretentive behavior of radiolabeled tamarind seeds formulations
MSP4, MSP5, and MSP6 were .24 h, although MSP1, 
MKP1, MKP2, and MSP2 disintegrated within 1 h.
in vitro drug-release study
The in vitro dissolution study helped in understanding the 
influence of polymers on the rate of drug release. It was 
observed that the drug-release profile was greatly depen-
dent on the types of polymers and their concentrations; this 
information is presented in Figure 3. The presence of TKP/
TSP in a formulation improved the rate of drug release in 
comparison with using xanthan alone. The formulations of 
MKP1/MSP1 and MSP2 with xanthan:TSP/TKP ratios of 
0:100 and 20:80 were not able to control the release for the 
estimated period of time, and they disintegrated within 1 h. 
MKP1 and MSP1 achieved 100% release in 2 h, MKP2 and 
MSP2 completely released the drug in 5 h, and the remaining 
eight formulations could sustain the release for 12 h. Figure 3 
illustrates the percentage of drug release as follows: MKP2 
(99.26%), MKP3 (97.87%), MKP4 (96.6%), MKP5 (94.0%), 
MSP3 (98.4%), MSP4 (97.7%), MSP5 (96.6%), and MSP6/
MKP6 (92.8%). Among all the formulations, MKP3 was 
found to be the optimal formulation; it contained 60 mg of 
TKP and 40 mg of xanthan; the FLT of this formulation 
(MKP3) was found to be 18 s and .90% of the drug had 
been released in 12 h. These in vitro data are consistent 
with previously published results and demonstrated that the 
formulation containing TKP could provide superior control 
release compared to the formulation containing TSP. The 
rate of drug release was prolonged for a longer time due 
to better gel-forming ability of the TKP polymer.34,36 This 
formulation had the highest similarity factor (f2) with com-
mercial formulation (65%). The mechanisms of release for 
Table 3 Physical properties of metformin hcl matrix tablets (mean ± sD)
Code Width 
(mm)a
Thickness 
(mm)a
Length 
(mm)a
Hardness 
(N)a
Drug 
content (%)b
Weight 
variation (mg)c
Friability 
(%)a
MKP1 10.1±0.1 4.6±0.0 18.4±0.0 136±2.0 98.9±0.2 764±1 0.39
MKP2 10.2±0.4 4.6±0.5 18.4±0.2 166±5.5 98.7±0.3 764±1 0.33
MKP3 10.1±0.6 4.6±0.3 18.4±0.1 208±8.5 98.4±0.7 764±2 0.39
MKP4 10.1±0.0 4.6±0.1 18.4±0.5 257±5.0 97.8±2.0 764±1 0.36
MKP5 10.1±0.9 4.6±0.8 18.4±0.2 277±5.5 98.7±1.4 765±1 0.36
MsP1 10.1±0.6 4.6±0.4 18.4±0.2 120±7.5 98.0±2.7 765±1 0.49
MsP2 10.1±0.4 4.6±0.6 18.4±0.3 149±4.6 98.6±1.6 764±1 0.45
MsP3 10.1±0.6 4.6±0.3 18.4±0.3 186±3.0 97.3±1.0 764±1 0.39
MsP4 10.1±0.5 4.6±0.8 18.4±0.5 220±4.9 98.8±0.4 765±1 0.35
MsP5 10.1±0.9 4.6±0.8 18.4±0.5 252±7.4 98.1±0.1 764±1 0.31
MsP6/MKP6 10.1±0.7 4.6±0.9 18.4±0.3 280±5.0 98.8±0.3 764±1 0.27
Notes: an=10, bn=3, and cn=10.
Abbreviations: hcl, hydrochloric acid; sD, standard deviation.
Figure 2 The floating behavior of different formulations prepared using an equal concentration of NaHCO3 (n=3).
Abbreviations: hcl, hydrochloric acid; nahcO3, sodium bicarbonate; s, seconds.
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the above formulations were obtained by calculating the 
R2 value. The first-order, zero-order, Hixson–Crowell, and 
Higuchi models corresponded to the release data of each 
formulation. When the maximum value of the correlation 
coefficient is considered, the drug-release profile for all the 
prepared formulations appears to fit with the Hixson–Crowell 
and first-order models. The linearity of the first-order model 
was higher compared to the zero-order kinetics plot. This 
indicated that the release of drug from this formulation was 
dependent on the concentration. Hixson–Crowell was the 
dominant drug-release mechanism for all the formulations 
because the Hixson–Crowell plot had higher linearity when 
compared with the Higuchi model. This showed that the drug 
was being released by the Hixson–Crowell method from the 
matrix surface instead of diffusion. This occurred due to the 
strong matrix formed in the high proportion of polymer which 
contains a narrow gap space, resulting in limited and slow 
diffusion of the drug. 
characterization of the optimal formulation 
using Dsc
Pure metformin HCl displayed an endothermic peak 
at 233.09°C for instance of drug melting point. The presence 
of the sharp peak indicated high purity of an anhydrous crys-
talline molecule.45 The thermogram detected broad peaks at 
115°C and 121.15°C of pure xanthan and pure TKP, respec-
tively. These findings demonstrated that the polymers melting 
transition happened at these temperatures. The broad peaks 
in melting endotherm also indicated the multiple thermal 
characteristics of TKP and xanthan. From the DSC thermo-
grams of the crushed tablets, the represented peaks correlated 
to the melting endotherm of pure metformin HCl, xanthan, 
and TKP. At the melting point of the crushed tablet, no con-
siderable new peak or variation was noticed. This specified 
that no solid-state interaction occurred; in addition, the drug 
and polymers were compatible. However, there were some 
changes in the melting transition of the ingredients in the 
DSC thermogram of the crushed tablets. The peak’s height 
was shorter when compared with the thermograms of the pure 
forms, which may be due to differences in the concentrations 
of the ingredients in the samples, as other excipients in the 
sample act as impurities to the pure polymers; the peaks 
became broader and less pronounced than the peaks of the 
pure polymer (Figure 4).
characterization of the optimal formulation 
using FTir 
FTIR is widely used for molecular structural investigations, and 
a specific range of the wavelengths represents different func-
tional groups present in the tested sample. As seen in Figure 5, 
major peaks were identified at 3,568.37, 3,402.80, 1,935.40, 
1,834.4, 1,077.3, and 963.3/cm for the formulated matrix 
tablets. The peaks of metformin HCl were detected at 3,369.4, 
3,295.75, 3,157.01, 1,565.01, 1,064.23, and 938.16/cm. 




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Figure 3 The cumulative percentage of metformin hcl release from MKP1–MKP6 and MsP1–MsP6 formulations and c.er within 12 h (n=3).
Abbreviations: hcl, hydrochloric acid; c.er, commercial formulations; h, hours.
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The TKP and xanthan main peaks were spotted at 1,040.64, 
1,645.26, 2,925.27, 3,301.86/cm, and 3,374.48, 2,919.59, and 
1,053.84/cm, respectively. The tablet spectrum showed no 
new peaks, indicative of no chemical alterations between the 
ingredients through the tablet preparation process. 
characterization of the optimal formulation 
using XrD
Phase identification of a crystalline material is mostly used 
by XRD which is a quick analytical tool, and it offers cell 
dimension information as well. Figure 6 displays the X-ray 
diffractograms of TKP, pure drug, xanthan, and their relevant 
formulations (MKP3). The sharp distinguishing peaks of 
metformin HCl were observed at angles (2θ°) of 13, 17.58, 
22.5, 23.25, 25.25, 27.5, 28.6, 29.55, and 30.85, which 
indicates drug crystallinity. Extensive peak of TKP was 
displayed at 19.7, whereas a peak by xanthan appeared at 
an angle of 20.4 (2θ°), demonstrating both polymers natures 
are amorphous. Lesser significant peaks were exhibited by 
xanthan than TKP, possibly because of its greater amorphous 
nature. XRD of MKP3 formulation shows a decline in the 
pure drug crystallinity as reflected in the diffractogram. There 
was no remarkable change in the formulation peaks except 
the polymers peaks. No noticeable alteration was detected 
in the pattern of XRD, which might be due to the physical 
interactions that happened during tablet compression or 
polymers dispersion during the mixing. 
in vivo imaging study of the rabbits
The in vitro dissolution study revealed that size reduction and 
the presence of samarium oxide (Sm
2
O
3
) in the formulation 
did not show any significant effect on the FLT or drug-release 
profile of the tablets. Furthermore, gamma spectroscopy data 
confirmed that neutron activation of the tablets produced no 
unwanted radioactive by-products.34,36 The in vitro dissolu-
tion result of the optimal formulation (MKP3) was compared 
with the MKP3-Sm formulation which contained 152Sm. 
The drug-release profile of samarium in this formulation 
was compared with metformin HCl in MKP3 formulation; 
the similarity factor was calculated and 68% similarity was 
achieved; so the release profile of 153Sm was considered as 
the release profile of metformin HCl (Figure 7). 
Radionuclide 153Sm
2
O
3
 has an effective half-life of 1.93 days 
and emits γ and β radiations. For the last 20 years, 153Sm
2
O
3
 
has been used as a radiotracer in numerous pharmacoscin-
tigraphy research studies for reasons such as its availability, 
proper gamma energy, easy production, and minimal 
radiation exposure.46 153Sm
2
O
3
 is chemically stable and 
water insoluble; therefore, it will not be absorbed into the 
blood plasma during its transit in the GI tract; it is excreted 
through feces from the body and eventually decays to 153Eu 
as a stable nuclide.37

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Figure 6 X-ray diffraction of powder from the crushed tablets of MKP3, pure metformin hcl, TKP, and xanthan.
Abbreviations: hcl, hydrochloric acid; TKP, tamarind kernel powder; cPs, counts per second.
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Figure 7 Comparison of the drug-release profiles of the optimal formulation with 
(MKP3-sm) and without (MKP3) 152sm (n=3).
Abbreviation: h, hours.
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The objective of in vivo gamma scintigraphy study was 
to validate the in vitro test results of the optimal formula-
tion. Hybrid imaging of SPECT-CT was chosen because 
it provides excellent information on both anatomy and 
physiology. The activity of the radiotracer (153Sm) was clearly 
seen on the 3D images with anatomical details. Patterns of 
the SPECT-CT images of rabbit’s stomach at different times 
are shown in Figures 8 and 9. The images display the kinetic 
of the 153Sm activity, which represents the kinetics of the 
drug, throughout the GI system of the rabbit over a period 
of 12 h. The results represent a prolonged gastric retention 
time and the release of the drug in all the rabbits administered 
with MKP3 formulation (Figure 8). In contrast, the control 
formulation showed shorter gastric retention time, and the 
drug was released rapidly throughout the period of imaging 
(Figure 9). This study revealed that gastroretentive proper-
ties of the MKP3 formulation were not altered by gastric 
emptying. The drug-release profiles for MKP3 (tested both 
in vivo and in vitro) and the control formulation are shown 
in Figure 10. The MKP3 release at 1, 2, 4, 6, 8, 10, and 12 h 
was found to be 25%, 40.3%, 65.8%, 75.9%, 79.9%, 88.2%, 
and 97.4%, and for the control formulation the values were 
55.2%, 80.3%, 85.0%, 88.5%, 91.5%, 94.8%, and 95.0%, 
respectively. The obtained in vivo gamma scintigraphy 
results were similar to those of previously published studies, 
and it confirmed and proved that using a gel-forming agent 
such as TKP could sustain the drug release and that tablets 
will remain in the stomach for longer period of the time with 
optimum release rate.34,36 
Pharmacokinetic study
The calibration curve was obtained by plotting the ratio 
of the chromatographic peak area (metformin HCl) versus 
concentration of metformin HCl. Samples were prepared and 
injected on the same day. The calibration curve was linear 
in the given range (R2=0.9983). Estimated pharmacokinetic 
parameters are presented in Table 4 and Figure 11. 
Pharmacokinetic study of data shows increase in AUC 
and T
max
 of the sample administered with gastroretentive 
formulation of metformin HCl compared to the control for-
mulation containing metformin HCl alone without polymers. 
A 4 h delay was obvious in T
max
, which can be justified due 
to the sustaining release property of the gastroretentive 
formulation. The bioavailability was increased because of 
K
K
K
K
K
K
K
K
Figure 8 example of sPecT-cT images of gastroretentive matrix tablet (MKP3) formulation in the rabbit (rabbit no 2) (n=3).
Abbreviations: h, hours; cT, computed tomography; sPecT, single-photon emission computed tomography.
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K
K
K
K
K
K
K
K
Figure 9 representative gamma scintigraphy images of control formulation (without polymer and gas forming agent) in the rabbit (n=3).
Abbreviation: h, hours.





       7LPHK
7KH
FXP
XODW
LYH

RIG
UXJ
UHOH
DVH
G
     
0.3LQYLYR 0.3LQYLWUR &RQWURO
Figure 10 Comparison of the drug-release profiles obtained from the MKP3 formulation (tested both in vitro and in vivo) and the control formulation (in vivo) (n=3).
Abbreviation: h, hours.
Table 4 Pharmacokinetic parameters of metformin hcl in plasma samples (n=6, mean ± sD)
Treatment AUCo–t (μg⋅h/mL) Cmax (μg/mL) Tmax (h) T1/2 (h)
Metformin hcl alone 1,410.49±23.65 205.76±3.65 4.00±00 2.81±0.65
gastroretentive formulation 1,759.19±15.67 204.20±5.76 8.00±00 2.85±0.22
Abbreviations: hcl, hydrochloric acid; sD, standard deviation; h, hours.
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
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LRQ
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Figure 11 Plasma metformin concentration vs time profiles after oral administration of gastroretentive and control formulations to healthy rabbits.
Abbreviations: h, hours; hcl, hydrochloric acid.
the polymer’s ability to form a strong matrix tablet and 
delay the release; so a greater amount of the drug reaches 
systemic circulation (this is depicted by the higher AUC 
for the gastroretentive formulation compared to the control 
formulation [P,0.05]). The aim of the therapy is to achieve 
a steady state blood level that is therapeutically effective 
and nontoxic for an extended period of time. The present 
study concurs with this aim where the C
max
 values between 
the control formulation and the gastroretentive formulation 
are significantly the same (P.0.05); Figure 11 shows that 
the maintenance of C
max
 for the optimized preparation is 
extended. The objective of gastroretentive formulation is to 
maintain a therapeutic blood level over an extended period, 
so the drug must enter the circulation at approximately the 
same rate at which it is eliminated. The elimination rate is 
quantitatively described by the half-life (T
1/2
). This study 
clearly shows that the half-life of a normal tablet and the 
optimized tablet exhibit significantly the same (P.0.05) 
half-life for both preparations (Table 4).
Conclusion
The in vitro data revealed that tamarind and xanthan are 
good candidates for sustained-release formulation. Among 
all the formulations, MKP3 with a TKP:xanthan ratio of 3:2 
showed the best sustained-release properties with relatively 
short FLT; hence, it was selected as the optimal formulation 
in this study. The in vitro data were validated by in vivo 
scintigraphy imaging and further confirmed that the MKP3 
formulation successfully prolongs the gastric retention time 
by its swelling and floating behavior; in addition, a sustained 
release of .12 h was achieved. This formulation has poten-
tial to be developed further for clinical trials in humans, 
particularly for diabetes II mellitus patients. The in vitro 
data indicated that low concentrations of TKP and TSP were 
insufficient for controlling drug release in the dosage form. 
In addition, this formulation had 61% similarity with the in 
vivo result obtained from the gamma scintigraphy study of 
the rabbits and may be a potential candidate for use as an 
excipient in sustained-release formulations. 
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